Michael Vogelbaum, MD, PhD

216.636.0007

Michael Vogelbaum, MD, PhD
Department: Brain Tumor and Neuro-Oncology Center
Associate Director
Location: Cleveland Clinic Main Campus
Mail Code ND40
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.636.0007
DeskDesk:216.444.8564
WorkFax:216.444.2682
Michael Vogelbaum, MD, PhD
Department: Neurological Surgery
Location: Cleveland Clinic Main Campus
Mail Code ND40
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.636.0007
DeskDesk:216.444.8564
WorkFax:216.444.2682
Michael Vogelbaum, MD, PhD
Department: Gamma Knife Center
Location: Cleveland Clinic Main Campus
Mail Code ND40
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.636.0007
DeskDesk:216.444.8564
WorkFax:216.444.2682
Michael Vogelbaum, MD, PhD
Department: Cancer Biology
Location: Cleveland Clinic Main Campus
Mail Code ND40
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.636.0007
DeskDesk:216.444.8564
WorkFax:216.444.2682
Michael Vogelbaum, MD, PhD
Department: Taussig Cancer Institute
Location: Cleveland Clinic Main Campus
Mail Code ND40
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.636.0007
DeskDesk:216.444.8564
WorkFax:216.444.2682
Surgeon:
Yes
Treats:
Adults Only

Biographical Sketch

Michael A.Vogelbaum, MD, PhD, FACS, has been a member of the professional Staff in the Cleveland Clinic’s Department of Neurological Surgery since 1999. A graduate of the University of Virginia School of Medicine, Charlottesville, Va., he received his specialty training in neurosurgery at the Barnes-Jewish Hospital, St. Louis, Mo. He is board-certified in neurological surgery.

Specializing in the diagnosis and treatment of benign and malignant tumors of the brain and spinal cord, Dr. Vogelbaum also is interested in stereotactic (image-guided) surgery, Gamma Knife therapy and the molecular biology of brain tumors. He has joint appointments with the Cleveland Clinic Gamma Knife Center and the Lerner Research Institute’s Department of Cancer Biology. He is Associate Director of the Brain Tumor and NeuroOncology Center and Director of the Center for Translational Therapeutics at Cleveland Clinic.

In addition to his clinical duties, Dr. Vogelbaum is an active and enthusiastic Research Scientist. He was the recipient of the prestigious American Association of Neurological Surgeons Young Clinician Investigator Award, and receives support and funding from the American Cancer Society, the National Institutes of Health and the Wolf Family Foundation. He and the members of his research laboratory are presently investigating new approaches for the treatment of primary and metastatic brain tumors

Education & Fellowships

Residency - Barnes-Jewish Hospital
Neurological Surgery
St. Louis, MO USA
1999
Internship - Barnes-Jewish Hospital
General Surgery
St. Louis, MO USA
1993
Medical School - University of Virginia School of Medicine
Charlottesville, VA USA
1992
Doctorate - University of Virginia
Biomedical Engineering
Charlottesville, VA USA
1992
Undergraduate - Johns Hopkins University
Baltimore, MD USA
1985

Certifications

  • Neurological Surgery

Specialty Interests

benign and malignant tumors of the brain and spinal cord, gamma knife, molecular biology of brain tumors clinical and translational trials, stereotactic surgery, benign brain tumors (meningiomas, schwannomas), Brain Metastases, brain tumors, CNS metastatic disease, gamma knife and radiosurgery, Gamma Knife Radiosurgery, tumors of the brain and spine

Awards & Honors

  • Best Doctors in America, 2006, 2007
  • Research funding,  Wolf Family Foundation

Memberships

  • American Association of Neurological Surgeons
  • Congress of Neurological Surgeons
  • Society for NeuroOncology
  • American Society for Clinical Oncology
  • American Association for Cancer Research

Treatment & Services

  • Brain Biopsy
  • Brain Tumor Diagnosis
  • Brain Tumor Management
  • Brain Tumor Surgery
  • Clinical Trials
  • Cranial Radiosurgery
  • Craniotomy for Brain Tumor
  • Gamma Knife Radiosurgery
  • Gamma Knife Treatment
  • Lumbar Puncture (Spinal Tap)
  • Minimally Invasive Surgery
  • Neurological Surgery
  • Neurosurgery
  • Stereotactic Brain Biopsy
  • Stereotactic Radiosurgery
  • Stereotactic Surgery

Specialty in Diseases and Conditions

  • Adult Brain Tumors
  • Anaplastic Astrocytomas
  • Anaplastic Oligodendrogliomas
  • Astrocytoma
  • Benign Brain Tumors
  • Benign Tumors of the Brain
  • Benign Tumors of the Spinal Cord
  • Brain Cancer (Brain Tumor)
  • Brain Lymphoma
  • Brain Metastases
  • Ependymomas
  • Glioblastoma Multiforme
  • Laboratory Research of Brain Tumors
  • Malignant Gliomas
  • Malignant Tumors of the Brain
  • Malignant Tumors of the Spinal Cord
  • Meningioma
  • Metastatic Cancer
  • Oligodendroglioma
  • Sarcomas of the Brain or Head
  • Schwannoma

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 7/26/2013, Dr. Vogelbaum has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Vogelbaum receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Merck & Co., Inc.

Royalty Payments. Dr. Vogelbaum receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:

  • Infuseon Therapeutics, Inc.

Equity. Dr. Vogelbaum owns stock or stock options in the following companies for activities as a founder, inventor, discover, developer:

  • Infuseon Therapeutics, Inc.

Fiduciary Role. Dr. Vogelbaum serves in a fiduciary capacity, such as an elected officer, director or chief medical officer, for the following companies or other entities:

  • Infuseon Therapeutics, Inc.

Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Vogelbaum may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:

  • Infuseon Therapeutics, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English
Cleveland Clinic Mobile Site